With appreciation for feedback from Mark Fendrick, Director of the Value-Based Insurance Design (V-BID) Center at the ...
Fifteen prescription medications will be the focus of federal price negotiations that could lower prices for Medicare patients.
New presentations include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion, as well as full primary results from the Phase 3b ELARA trial in patients treated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results